Published in Concours Med on April 07, 1951
Differentiation of hemophilia into two groups; a study of thirty-three cases. N Engl J Med (1953) 1.42
[Therapeutic results in the use of human serum gamma globulins; survey of 6, 602 cases. I. Main indications for their use in infections diseases]. Presse Med (1958) 1.39
[Preparation of a fraction rich in prothrombin, proconvertin, Stuart factor and antihemophilic factor B (P.P.B. fraction)]. Pathol Biol (Paris) (1959) 1.39
[Deficiency of antihemophilic factor A in a girl associated with bleeding disorder]. Rev Hematol (1953) 1.34
[Not Available]. Rev Hematol (1949) 1.25
[Differential characteristics of Hageman & P.T.A. factors; role of contact in the initial phase of coagulation]. Rev Fr Etud Clin Biol (1958) 1.21
[Umbilical cord blood; complete study of its coaguability, comparison with maternal blood]. Etudes Neonatales (1952) 1.20
[Fatal hemorrhagic syndromes with total incoagulability and with fibrinolysis; in pulmonary exeresis]. Rev Hematol (1952) 1.15
[Analytical study on Quick test; determination of prothrombin, proconvertin, and proaccelerin]. Sang (1952) 1.15
Preparation of a human plasma fraction rich in prothrombin, proconvertin, Stuart factor, and PTC and a study of its activity and toxicity in rabbits and man. J Lab Clin Med (1959) 1.14
[Not Available]. Sem Hop (1948) 1.14
Hageman trait and PTA deficiency; the role of contact of blood with glass. Br J Haematol (1959) 1.13
Measurement of thromboplastic factors and profactors in plasma. I. Deficits in thromboplastin; study of reagents; measurements of antihemophilic and of platelet activities. J Lab Clin Med (1953) 1.13
[Treatment of hemophilia B with a plasma fraction rich in antihemophilic B factor (P.P.B.)]. Pathol Biol (Paris) (1959) 1.11
[Grave hemorrhages during thoracic surgery from blood incoagulability due to fibrinolysis]. Mem Acad Chir (Paris) (1951) 1.03
A new adsorption agent for coagulation factors. J Clin Pathol (1959) 1.01
[Electron microscope study of lymphoid leukemia with intracytoplasmic crystals]. Rev Hematol (1960) 0.96
[Determinations of properdin; technical study]. Rev Fr Etud Clin Biol (1957) 0.95
[Technical modifications of the in vitro heparin tolerance test]. Sem Hop (1951) 0.93
[Thromboplastin formation in platelet disorders; study of 34 cases by Biggs and Douglas test]. Acta Haematol (1955) 0.90
[Willebrand-Jürgens syndrome and thrombopathies; study of 66 cases; attempt at classification]. Rev Hematol (1954) 0.90
The "in vitro" heparin tolerance test in the control of dicumarol therapy. Acta Med Scand (1951) 0.90
[Heparin tolerance test in vitro in hemorrhagic syndromes and thrombosis]. Sem Hop (1950) 0.89
[Action of proteolytic enzymes on whole blood in vitro; alterations in coagulation factors and in complement]. Sem Hop (1956) 0.88
[Physiopathology of hemorrhage in thrombocythemia; study of hemostasis in 27 patients]. Sang (1957) 0.86
[Heparin tolerance test in vitro; hypocoagulability test, its application in diagnosis of hemorrhagic syndromes; hypercoagulability test, its application in the diagnosis of thrombosis]. Rev Hematol (1950) 0.86
[Preparation of a human plasmatic fraction rich in factor VIII (antihemophilic A) and poor in fibrinogen]. Nouv Rev Fr Hematol (1962) 0.86
[Pathological variations of complement and properdin in man]. Acta Haematol (1959) 0.85
[Fatal hemorrhagic syndromes with total incoagulability by defibrination and with fibrinolysis following abortion by injection of Javelle water; problem of defibrination in obstetrics and gynecology]. Rev Hematol (1952) 0.85
[New data on the Hageman and P.T.A. factors and on the "contact"]. Rev Fr Etud Clin Biol (1959) 0.85
[New diagnostic method in hemophilia; determination of antihemophilic factors A and B]. Sang (1953) 0.84
[Alteration of coagulation factors in fibrinolysis in vivo; value of proaccelerin deficiency in diagnosis of defaced or latent proteolysis]. Sem Hop (1956) 0.82
[Hemorrhagic syndrome with fibrinolysis associated with cancer of the prostate]. Presse Med (1955) 0.81
[A new adsorbant for coagulation factors: bentonite]. Rev Hematol (1959) 0.81
[CONGENITAL DEFICIENCY OF THE FIBRIN STABILIZING FACTOR (FACTOR XIII). STUDY OF 2 CASES]. Nouv Rev Fr Hematol (1964) 0.81
[A case of congenital hypoconvertinemia]. Sang (1955) 0.80
[Biological study of two cases of congenital afibrinogenemia]. Rev Hematol (1955) 0.80
[Congenital proaccelerin deficiency (factor V); various new data]. Thromb Diath Haemorrh (1958) 0.79
[Electrophoretic study of 86 cases of proteinuria (albuminuria); proteinuria in myeloma and nephropathy]. Presse Med (1953) 0.79
The effect of intravenous injection of trypsin inhibitor on the coagulation of blood. Blood (1948) 0.79
[Test of platelet-activity of the serum]. Rev Fr Etud Clin Biol (1957) 0.78
[Half-life of true prothrombin (factor II)]. Nouv Rev Fr Hematol (1963) 0.78
[Not Available]. Sang (1954) 0.78
[Separation of fibrinogen and of the antihemophilic factor A]. Rev Hematol (1958) 0.77
[Hageman factor deficiency]. Sang (1957) 0.77
[Antihemophilic B factor deficiency with prolongation of bleeding time]. Sang (1957) 0.77
Study of prothrombin consumption; practical interest for the diagnosis of hemorrhagic diseases; study of 89 cases. Acta Med Scand (1950) 0.77
Inhibitors of blood coagulation. 4. Natural inhibitors. Thromb Diath Haemorrh (1962) 0.76
[Study of a case of congenital hypoprothrombinemia]. Nouv Rev Fr Hematol (1963) 0.76
[Not Available]. Bull Mem Soc Med Hop Paris (1955) 0.75
[The National Center for Blood Transfusion]. Tech Hosp Med Soc Sanit (1955) 0.75
[A new case of congenital thrombocytic hemorrhagic dystrophy]. Presse Med (1952) 0.75
[Physiopathology of hemorrhages]. Presse Med (1950) 0.75
[Vascular fragility and production of estroids by adrenal cortex in children]. Sem Hop (1954) 0.75
[On hematological examination during pregnancy]. Concours Med (1951) 0.75
[The physiology of hemostasis and the large hemorrhagic syndromes]. Rev Fr Odontostomatol (1953) 0.75
[New anticoagulants useful in therapy]. Vie Med (1956) 0.75
[Disorders of the blood composition in acute leukemias; biological and therapeutic study]. Sang (1950) 0.75
[Attempted electrophoretic identification of resorcidine]. Sang (1952) 0.75
[List of blood products and preparation of blood derivatives (excluding gamma globulins)]. Sang (1956) 0.75
[Surgery of patients with hemorrhagic tendency]. Presse Med (1956) 0.75
[Not Available]. Ann Biol Clin (Paris) (1949) 0.75
[Value of anticoagulants in the treatment of pulmonary emboli]. Presse Med (1957) 0.75
[Anticoagulants]. Rev Pathol Comp (1952) 0.75
[Heparin tolerance test in vitro; its technique its clinical interest]. Ann Biol Clin (Paris) (1952) 0.75
[Surgery in patients with hemorrhagic tendency]. Presse Med (1956) 0.75
[Not Available]. Rev Fr Etud Clin Biol (1956) 0.75
[Not Available]. Rev Prat (1956) 0.75
[Present concept of blood coagulation]. Rev Prat (1951) 0.75
[Not Available]. Prog Med (Paris) (1948) 0.75
[Hypoprothrombinemia secondary to dicoumarin therapy; shock due to prolonged vitamin K2 therapy and perfusions and spectacular cure with vitamin K1]. Sang (1952) 0.75
Hemorrhagic diathesis associated with the presence of an anticoagulant in circulating blood; case report and laboratory studies. Blood (1948) 0.75
[New data concerning the anticoagulant action of a neodyme salt]. Rev Hematol (1957) 0.75
[Society of Hemophiliacs]. Rev Prat (1956) 0.75
[Conditions in which one should proceed in taking blood]. Rev Hyg Med Soc (1955) 0.75
[Incoagulability of blood due to afibrinogenemia]. Presse Med (1952) 0.75
[Treatment of thromboses with anticoagulants]. Ann Soc Angeiol Histopathologie (1951) 0.75
[Not Available]. Paris Med (1950) 0.75
[Study of thrombosis; indications and use of anticoagulants in the treatment of thrombosis]. Sem Hop (1950) 0.75
[Use of injectable fibrinogen in therapy]. Sem Hop (1956) 0.75
[Not Available]. Sem Hop (1948) 0.75
[A constitutional hemorrhagic disease characterized by isolated prolongation of the bleeding time (Willebrand's disease; study of 9 cases)]. Rev Hematol (1950) 0.75
[Not Available]. Bull Mem Soc Med Paris (1907) (1950) 0.75
[Acute hemorrhagic syndromes with coagulation disorders]. Rev Hematol (1952) 0.75
[Appearance of an antithrombin following thrombin injections in a hemophilic having presented a circulating anticoagulant]. Rev Hematol (1953) 0.75
[Use of human plasma gamma globulins in prevention of measles; results of 1,259 cases]. Presse Med (1956) 0.75
[Thrombosis factors and the mechanism of action of anticoagulants on hemostasis]. Therapie (1955) 0.75
[Therapeutic use of gamma globulin]. Sem Hop (1956) 0.75
[Circulating anticoagulant of antithromboplastic activity]. Rev Fr Etud Clin Biol (1956) 0.75
[Prolongation of clotting time combined with a deficiency of anti-hemolytic factor A]. Rev Fr Etud Clin Biol (1956) 0.75
[Necessity of a laboratory]. Concours Med (1950) 0.75
Anticoagulant activity of the trypsin inhibitor from soya bean flour. Proc Soc Exp Biol Med (1946) 0.75
[Hemorrhagic syndromes with isolated impairment of capillary resistance; study of 38 cases]. Sang (1950) 0.75
[Hypercoagulability]. Rev Fr Etud Clin Biol (1956) 0.75
[Polycythemia vera and the Budd-Chiari syndrome; clinical, biological & endoscopic study; traitement with P34 and tromexam; apparent recovery]. Rev Med Chir Mal Foie (1956) 0.75
[Not Available]. Presse Med (1949) 0.75
[Extension of prothrombin time in relation to a deficit in "accelerin"]. Arch Fr Pediatr (1951) 0.75
[Complete failure of vitamin B12 in a case of familial hemophilia]. Rev Hematol (1953) 0.75
[Study of lipoproteins in human and experimental arteriosclerosis by electrophoresis and non-specific reactions of proteins; effect of heparin]. Sem Hop (1953) 0.75
[Pancytopenia of splenic origin secondary to Banti's fibroadenia]. Sang (1951) 0.75